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Abstract 
Introduction: The number of genetic tests, mostly real-time PCRs, to detect antimicrobial 
resistance (AMR) determinants and predict AMR in Neisseria gonorrhoeae is increasing. 
Several of these assays are promising, but there are important shortcomings and few assays 
have been adequately validated and quality assured.  
Areas covered: Recent advances, focusing on publications since 2012, in the development and 
use of molecular tests to predict gonococcal AMR for surveillance and for clinical use, 
advantages and disadvantages of these tests and of molecular AMR prediction compared with 
phenotypic AMR testing, and future perspectives for effective use of molecular AMR tests for 
different purposes.   
Expert Commentary: Several challenges for direct testing of clinical, especially extra-genital, 
specimens remain. The choice of molecular assay needs to consider the assay target, quality 
controls, sample types, limitations intrinsic to molecular technologies, and specific to the 
chosen methodology, and the intended use of the test. Improved molecular- and particularly 
genome-sequencing-based methods will supplement AMR testing for surveillance purposes, 
and translate into point-of-care tests that will lead to personalized treatments, while sparing 
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the last available empiric treatment option (ceftriaxone). However, genetic AMR prediction 
will never completely replace phenotypic AMR testing, which detects also AMR due to 
unknown AMR determinants. 
Keywords: Neisseria gonorrhoeae, antimicrobial resistance, molecular testing, NAAT, 
ceftriaxone, ciprofloxacin, azithromycin, penA, gyrA, 23S rRNA  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.Introduction 
Gonorrhea is a major public health problem and in 2012 the WHO estimated 78 million new 
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annual cases among adults globally. The highest number of cases was in the WHO Western 
Pacific Region (35.2 million), followed by the WHO South-East Asian Region (11.4 million), 
WHO African Region (11.4 million), WHO American Region (11.0 million), WHO European 
Region (4.7 million), and WHO Eastern Mediterranean Region (4.5 million) [1]. These 
Neisseria gonorrhoeae (NG) infections can, if not appropriately treated, result in severe 
complications and sequelae, including pelvic inflammatory disease, ectopic pregnancy, and 
infertility, as well as enhance the transmission and acquisition of HIV [2,3]. Effective, 
accessible and affordable antimicrobial treatment is the mainstay for management and control 
of gonorrhea, i.e., supported by effective prevention, diagnostics, contact notification, and 
epidemiological surveillance.  
It is a major concern that NG has developed resistance to all antimicrobials previously 
recommended for treatment of gonorrhea including sulphonamides, penicillins, tetracyclines, 
spectinomycin (SPC), fluoroquinolones, macrolides and early-generation as well as, more 
rarely, extended-spectrum cephalosporins (ESCs) [2]. The injectable ESC ceftriaxone (CRO) 
or dual antimicrobial therapy (usually CRO 250-500 mg plus azithromycin (AZM) 1-2 g) are 
currently the only appropriate options for empirical first-line therapy in most countries 
worldwide [3,4]. WHO has published a global action plan including numerous actions to 
mitigate the emergence and spread of AMR NG [3], strongly emphasizing the need for 
enhanced NG AMR surveillance globally. However, in many well-resourced settings nucleic 
acid amplifications tests (NAATs) have replaced culture for NG detection and in many less-
resourced settings only syndromic management of gonorrhea is applied, resulting in a loss of 
capacity to culture NG and perform phenotypic AMR testing. Consequently, sensitive and 
specific tests for the molecular detection of AMR mechanisms or determinants to predict the 
NG AMR would be exceedingly valuable. These tests should ideally also be rapid and capable 
of being performed at the point-of-care (POC) to additionally guide personalized treatment of 
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each patient. Nevertheless, despite that many in-house- or laboratory-developed tests for NG 
AMR prediction were designed particularly during the last decade, no such test has yet 
become commercially available.  
The objectives of this paper were to review recent advances, focusing on publications 
since 2012, in the development and use of molecular tests to predict gonococcal AMR for 
surveillance and for clinical use, advantages and disadvantages of these molecular tests and of 
molecular AMR prediction vs. phenotypic resistance testing, and finally provide some future 
perspectives for effective use of molecular tests to monitor NG AMR as well as to guide 
personalized treatment of gonorrhea at the POC.   
 
2. Molecular mechanisms and determinants for antimicrobial resistance in N. 
gonorrhoeae 
NG has shown an extraordinary ability to acquire or develop resistance to all antimicrobials 
used for treatment through i) enzymatic destruction/modification of the antimicrobial, ii) 
modification/protection of the target leading to decreased affinity to the antimicrobial, and iii) 
decreased influx and/or increased efflux of the antimicrobial. Some AMR determinants are 
directly linked to resistance to a particular antimicrobial, whereas others require a cumulative 
effect with other AMR determinants in order to achieve clinically relevant resistance. AMR 
mechanisms in NG were extensively reviewed recently [2].  
The main AMR mechanisms and/or determinants conferring resistance to the previous or 
current gonorrhea treatment options ciprofloxacin (CIP), AZM, ESCs and SPC are 
summarized in Figure 1.  
 
2.1. Ciprofloxacin (CIP) target resistance determinants 
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CIP resistance is mainly driven by mutations reducing fluoroquinolone affinity of the target 
enzymes DNA gyrase and topoisomerase IV. The main mutations associated with CIP 
resistance are found in the quinolone resistance-determining regions (QRDRs) of the gyrA 
gene, encoding one of the two subunits forming the DNA gyrase heterotetramer. Initial non-
synonymous mutations in codon 91 (most frequently encoding a GyrA S91F alteration) cause 
low- to intermediate resistance, with an additional mutation in codon 95 (e.g., GyrA D95N) 
further increasing the CIP MICs. Concomitant mutations in the parC gene, encoding one of 
the topoisomerase IV subunits, are required for high-level CIP resistance. The ParC D86N, 
S87N, S88P and E91A/K/G substitutions have been shown to increase CIP-resistance [2,5,6]. 
 
2.2. Azithromycin (AZM) target resistance determinants 
The C2611T and A2059G target mutations in the four 23S rRNA alleles have been associated 
with moderate- to high-level AZM resistance, respectively, with the resistance level 
dependent on the number of mutated alleles [2,7-9]. It is important to detect strains with only 
one mutated allele since, under macrolide selective pressure, the 23S rRNA mutations can be 
transferred to the other alleles through recombination [8]. 
Additionally, rarely identified erm genes, encoding rRNA methylases, can lead to 
decreased susceptibility to low-level AZM resistance [2,8,10,11]. 
 
2.3. Extended-spectrum cephalosporin (ESC) target resistance determinants 
Decreased susceptibility and resistance to ESCs are associated with the presence of mosaic 
penA alleles (the main ESC resistance determinant), encoding mosaic variants of the lethal 
target penicillin-binding protein 2 (PBP2) [2,12-16]. However, many different penA mosaic 
alleles exist, which result in widely different MICs of ESCs [2,13,17-19; 
https://ngstar.canada.ca/welcome/home]. NG strains harboring the mosaic penA alleles 
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XXXIV and X and with decreased susceptibility or resistance to ESCs have been associated 
with treatment failures in many parts of the world [2,13,20-22]. Notably, only one additional 
substitution in the mosaic penA XXXIV allele (i.e., A501P) results in high-level CRO 
resistance [19]. Nevertheless, ESC-resistant strains harboring a non-mosaic penA allele, with 
PBP2 A501 and G542/P551 alterations, have also been described, particularly in Asia [23-
26]. 
 
2.4. Spectinomycin (SPC) target resistance determinants 
High-level SPC resistance has mostly been caused by a C1192U mutation in the 16S rRNA 
target [2,27,28]. However, a Val25 deletion and K26E alteration in the ribosomal protein S5, 
encoded by the rpsE gene, are also associated with high-level SPC-resistance, whereas the 
T24P alteration confers low-level SPC resistance [28,29].  
 
2.5. Increased efflux 
Five efflux pump systems have been described in NG; MtrCDE, MacAB, NorM, MtrF and 
FarAB (Figure 2) [30-33]. The MtrCDE efflux pump has been shown to export several classes 
of antibiotics, including AZM and ESCs [30,34,35], whereas NorM and MacAB mainly 
export fluoroquinolones and macrolides, respectively [32,33]. 
Mutations causing an over-expression of the MtrCDE efflux pump have been associated 
with intermediate susceptibility and resistance to several antimicrobials. Among these, a 
mutation in the mtrR gene causing a G45D substitution in MtrR, a transcriptional repressor of 
the mtrCDE operon, is prevalent [36]. However, the most frequent mutations harbored by 
resistant isolates are located in the 13-bp inverted repeat sequence of the mtrR promoter, 
commonly a single A deletion [35]. 
 
2.6. Decreased influx 
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 Mutations in the porB1b gene (the penB resistance determinant) encoding alterations in only 
amino acid 120 (e.g., G120K) or in combination with amino acid 121 (e.g., G120D/A121D) 
in PorB1b result in decreased influx and, accordingly, decreased susceptibility to e.g., ESCs 
[2,37]. These mutations affect the AMR phenotype only in strains with concomitant 
overexpression of the MtrCDE efflux pump [38]. 
 
3. Molecular tests for prediction of antimicrobial resistance in N. gonorrhoeae 
Many methods for molecular prediction of NG AMR have been developed during the recent 
decade. The main characteristics of these molecular assays have been summarized in Table 1. 
 
3.1. Ciprofloxacin (CIP)  
As early as 2004, a duplex real-time (RT)-PCR assay was designed, which used Taqman 
probes to target the wild type (wt) sequence in the gyrA QRDRs, i.e. spanning codons 91 and 
95, and parC QRDR including codons 86-88 [39]. Analysis of 80 NG isolates showed 100% 
agreement between RT-PCR results, sequencing, and CIP MICs. However, a main limitation, 
common also to other recently proposed molecular AMR methods, was that no internal 
control for the detection of NG DNA was included in the assay.   
An improvement of this method included a marker for NG identification (dcmH) [40]. 
After validating the assay on 40 sets of linked urogenital samples and blinded testing of 
additional 33 NG positive urine specimens with paired NG isolates, sensitivity and specificity 
for the detection of CIP-susceptibility were 100% for the gyrA component of the assay, and 
95.5% and 86.1% for the parC component. Conversely, failure to detect both gyrA and parC 
amplicons from the same DNA sample was 96.9% sensitive and 100% specific in predicting 
CIP-resistance. No false-positive amplification of either gyrA or parC targets in other 
bacterial species was observed among 21 paired sets of DNA extracts prepared from clinical 
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specimens of patients with non-gonococcal urethritis. Detection of NG by targeting dcmH 
showed 100% sensitivity and 97.9% specificity for isolates and clinical specimens. However, 
false-positive reactions for dcmH due to the presence of Neisseria lactamica, Neisseria 
flavescens and Neisseria sicca were previously observed in a dcmH-based commercial NAAT 
for NG, indicating the potential for cross-reaction with commensal Neisseria species for this 
target [41]. In fact, some cross-reactivity with N. lactamica was observed when 26 non-
gonococcal isolates were further tested. Some false-positive results were also reported for the 
parC reaction [40]. No rectal and pharyngeal specimens were evaluated in the study, but these 
preliminary observations suggest that cross-reactivity for at least the dcmH and the parC 
reactions due to commensals may be expected. 
Another probe-based RT-PCR targeting the same mutations in the QRDRs of gyrA and 
parC (positions gyrA S91, gyrA D95and parC D86/S87/S88), also including an internal 
control probe for each gene that should produce a positive signal in NG presence, was applied 
to 252 NG isolates. The assay showed 100% correct results for gyrA S91 and parC 
D86/S87/S88, and 99.6% for gyrA D95 [42]. The limits of detection (LODs) were 5 pg 
DNA/reaction for both gyrA reactions and 5 fg DNA/reaction for parC. The assay was 
subsequently validated using 24 APTIMA Combo 2 CT/NG urogenital and extra-genital 
NAAT specimens with matched NG isolates. The overall RT-PCR concordance for each 
genetic marker was 100% for parC and 83.3% for both gyrA assays. Seven samples were 
undetermined in the gyrA assays, indicating that the lower sensitivity for the gyrA reactions in 
the clinical specimens was mainly due to the higher LOD compared to the parC reaction. One 
rectal specimen gave a false-positive result for gyrA D95. The specificity of the assay was 
also assessed by testing 50 non-gonococcal isolates, showing some cross-reactivity (both wt 
and single nucleotide polymorphism [SNP]) for all three reactions. However, none of 24 
tested NG-negative APTIMA specimens gave false-positive results for gyrA, and only two 
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pharyngeal swabs showed a cross-reaction for parC [42]. Nevertheless, additional testing of 
clinical specimens is crucial to thoroughly assess the potential for cross-reactivity. 
Most recent RT-PCR based approaches detect only SNPs in gyrA codon 91. For instance, 
a Taqman probe-based RT-PCR assay for detection of the GyrA S91F substitution was 
validated using 108 clinical specimens with paired CIP-resistant NG and 101 with CIP-
susceptible control strains [43]. The method showed a sensitivity and specificity of 100% and 
99%, respectively, compared to phenotypic CIP susceptibility. No cross-reactivity was 
observed testing six other Neisseria and Lactobacillus species. However, the panel was 
limited and no negative clinical specimens were tested. Accordingly, additional testing to 
exclude cross-reactivity with other non-gonococcal species is crucial. Additionally, gyrA wt 
or other NG specific markers were not detected in the assay, i.e. to avert the risk of false 
negatives due to low NG DNA loads. 
This limitation, i.e. lack of appropriate internal NG control, has been addressed in other 
assays. For instance, a Taqman-based RT-PCR assay that detects wt gyrA or the GyrA S91F 
alteration with two different probes showed 100% agreement with CIP susceptibility 
phenotype when 90 NG isolates were tested [44]. The method was further applied on 
urogenital (n=174) and extra-genital (i.e., pharyngeal and rectal; n=116) samples, NG-positive 
by the BD ProbeTec GC Qx Amplified DNA Assay providing a result for 90% (262/290) of 
the specimens, with most undetermined samples being extra-genital specimens. For the 234 
clinical specimens with paired gonococcal isolates from the same anatomical site, the 
sensitivity and specificity for detecting CIP susceptibility was 95.8% and 100%, respectively. 
Accordingly, absence of the GyrA S91F SNP demonstrated 100% positive predictive value 
for CIP susceptibility in all clinical specimens tested [44]. Nevertheless, no NG-negative 
clinical specimens, and especially extra-genital samples, were tested to assess cross-reactivity.  
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The concern of cross-reactivity was addressed in another RT-PCR method in which 
primers with “non-template” bases at the 3’-end in order to increase the specificity were 
designed [45]. This probe-based assay correctly distinguished gyrA wt and the GyrA S91F 
alteration in 70 NG isolates tested, whereas all non-gonococcal isolates (n=55) and NG-
negative clinical samples (n=171, including both rectal [n=27] and pharyngeal swabs [n=34]) 
gave negative results. When applied to 210 NG-positive clinical samples (including both 
rectal swabs (n=14) and pharyngeal swabs (n=7)) with paired NG isolates, 195 (92.9%) 
samples were successfully characterized, and for 194 samples the results were in agreement 
with phenotypic CIP susceptibility results. The single discordant sample harbored a mixed 
infection. Mixed infections in the same anatomical site were also discussed in a recent 
publication [46]. 
A RT-PCR with fluorescence resonance energy transfer (FRET)-probes coupled with 
melting curve analysis to detect gyrA wt or the GyrA S91F alteration was first published in 
2007 [47]. Evaluation of 96 male urine specimens with paired NG isolates from matched 
urethral samples, found amplification in 95 (99.0%). Sensitivity and specificity to detect CIP 
resistance was 93.2% (41/44) and 100% (51/51), respectively. Additionally, a CIP 
susceptibility genotype was predicted in 72% (72/100) NG-positive female urine samples 
previously tested using APTIMA Combo 2, but 28 (28%) samples failed to amplify [47]. The 
assay was also applied on 13 urogenital specimens, of which 2 (15.4%) tested gyrA S91F 
positive, in a small substudy [48]. A further evaluation of this assay showed 100% 
concordance with CIP susceptibility phenotypes in 100 isolates. Among 76 urine and swab 
specimens that tested NG-positive by the Cobas 4800 CT/NG system, the assay correctly 
classified 54 (71%) as gyrA wt or mutant, and in 116 Cobas NG-negative specimens no 
amplification occurred [49]. Most of the undetermined samples were urine (n=17), confirming 
the suboptimal sensitivity for this specimen type. No pharyngeal specimens were evaluated.  
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3.2. Azithromycin (AZM) 
Only one assay for detection of AZM resistance alone has been published [50]. This assay 
consisted of two probe-based RT-PCRs coupled with melting curve analysis targeting the 23S 
rRNA C2611T and A2059G mutations, respectively. To mitigate cross-reaction with other 
bacterial species, “non-template” bases were included at the 3’-end in the primer sequences, 
as previously described [45]. When testing 28 non-gonococcal isolates, including Neisseria 
mucosa (n=3), Neisseria cinerea (n=3), Neisseria subflava (n=11), N. sicca (n=3), N. 
lactamica (n=4), N. flavescens (n=1) and N. meningitidis (n=3), cross-reactivity with 26 and 
all 28 isolates could be observed for the 23S rRNA C2611T and A2059G targets, 
respectively. However, the cycle thresholds were higher, indicating that this strategy was able 
to limit the cross-reactivity. Nevertheless, when testing 90 NG-negative urogenital and extra-
genital samples, 33% (7/21) of pharyngeal samples were false positive. Of 70 NG isolates, all 
were correctly characterized, i.e. no isolates contained the 23S rRNA A2059G mutation and 
three AZM-resistant isolates (AZM MIC>2 µg/ml) harbored the 23S rRNA C2611T mutation. 
Three AZM-susceptible isolates harbored both 23S rRNA wt and C2611T mutated alleles, 
which illustrates that ≥3 mutated alleles are usually required for moderate AZM resistance 
(MIC>2 µg/ml) [7,8]. Finally, 87% (266/306) of NG NAAT-positive clinical samples (no 
pharyngeal samples) could be characterized by both 23S rRNA PCRs, whereas 13% (40/306) 
could not be characterized by one or both assays, likely due to low NG DNA loads. A 
limitation of the study was that there was only one clinical sample positive for the 23S rRNA 
C2611T mutation and none for the 23S rRNA A2059G mutation. Accordingly, further 
evaluation would be valuable, i.e. with clinical samples including NG strains with these 
mutations or NG-negative specimens spiked with NG isolates harboring those mutations. 
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3.3. Extended-spectrum cephalosporins (ESCs) 
Several assays to detect mosaic penA alleles associated with decreased susceptibility or 
resistance to ESCs have been developed. 
In 2008, a Taqman-based RT-PCR assay with one primer designed to match the Neisseria 
perflava- and the other the N. cinerea-like sequences in the NG mosaic penA gene, was 
published [51]. Among 70 NG isolates, the assay correctly identified 47 mosaic penA-
harboring isolates. The LOD of the assay was 10 copies/reaction. However, many mosaic 
penA alleles have now been described ([13]; https://ngstar.canada.ca/welcome/home), and it is 
unknown whether this method would detect all these mosaic penA alleles. Additionally, cross-
reactivity with commensals was assessed by testing only one N. cinerea and one N. perflava 
strain, and in silico analysis suggests cross-reactivity with some N. meningitidis strains. 
This mosaic penA PCR [51] has been used together with other RT-PCR assays for testing 
of bacterial strains and non-cultured clinical samples, NG-positive by an in-house PCR, in 
Australia [52,53]. Cross-reactivity with two N. meningitidis strains was confirmed when 
testing 100 non-gonococcal isolates. However, when applied to 192 NG-negative clinical 
specimens (142 urogenital and 50 pharyngeal samples), no false-positives were detected. This 
study also used two Taqman probe-based PCRs detecting the A501V PBP2 amino acid 
substitution and the A-deletion in the mtrR promoter region, respectively [52]. None of these 
newly designed assays showed any cross-reactivity when testing the 192 NG-negative clinical 
samples. The assays were also applied on 179 NG-positive clinical specimens with unknown 
sampling site. The A deletion in mtrR promoter was found in 24 samples, whereas all samples 
tested negative in the mosaic penA and A501V PCR assays [52]. Since the mosaic penA PCR 
and A501 PCR only detected mutant isolates, false-negative results due to limited NG DNA 
cannot be excluded. 
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The mosaic penA PCR developed in 2008 [51] has also been used in combination with a 
RT-PCR that specifically detects the mosaic penA XXXIV allele [53]. Fifty-nine (8.6%) 
isolates tested positive for a mosaic penA allele; 39 isolates possessed the mosaic penA 
XXXIV, four isolates the mosaic penA XXXVIII and 16 isolates a novel mosaic penA allele 
(LA-A). Fifteen (25%) of these isolates harboring a mosaic penA displayed an alert value of 
CRO MIC (≥0.125 µg/ml). The performance of the RT-PCR detecting the mosaic penA 
XXXIV was subsequently assessed by testing 71 NG isolates, 27 urine specimens (including 
three NG-culture-positive matched urethral swabs) and 20 NG-negative pharyngeal swab 
specimens. All thirty-nine isolates and three urine specimens with paired isolates containing 
the mosaic penA XXXIV allele were correctly identified. No cross-reactivity was seen for 
strains harboring the mosaic XXXVIII, LA-A or other penA alleles, or NG-negative urine and 
pharyngeal specimens. The sensitivity and specificity in detecting alert values of CRO MIC 
(≥0.125 µg/ml) was 100% and 57%, respectively [53]. These combined assays are valid tools 
for the detection of mosaic penA alleles, particularly mosaic penA XXXIV, in bacterial 
isolates. Nevertheless, for testing of clinical specimens further evaluations are recommended, 
including additional NG-positive and NG-negative samples, especially extra-genital 
specimens and additional mosaic penA alleles. Furthermore, the assay did not include 
detection of any NG-specific marker, so false negative results due to limited NG DNA cannot 
be excluded. 
A more comprehensive probe-based RT-PCR assay included detection of SNPs in penA, 
mtrR, porB, ponA, and one NG-specific marker (porA) [54]. The ponA and mtrR assays 
contained probes targeting wt or mutated alleles, while the porB assay contained a probe 
matching the wt allele sequence and the penA assay three probes specific for the mosaic and 
non-mosaic alleles. The LODs were 50 fg/reaction for porA, ponA, mtrR, and porB, and 500 
fg/reaction for penA. When initially testing 252 NG isolates, the agreement between the RT-
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PCR and sequencing was 100% for porA, ponA, and penA, 99.6% for mtrR, and 95.2% for 
porB (all negatives contained the porB1a allele instead of the targeted porB1b allele). 
Specificity was further assessed by testing 50 non-gonococcal isolates, showing cross-
reactivity with some non-gonococcal Neisseria, as well as other commensal species, for all 
markers except the NG-specific porA target. The cross-reactivity was further confirmed when 
testing 24 NG-negative urogenital and extra-genital specimens, i.e., three examined 
pharyngeal swabs showed cross-reactivity for the penA and porB targets. For 24 NG-positive 
APTIMA specimens with matched NG isolates, assay concordance was 100% for porB, 
95.8% for ponA and mtrR, and 91.7% for penA. One rectal specimen gave indeterminate 
results for ponA, mtrR, and penA. One pharyngeal specimen also had indeterminate penA 
result, likely suggesting cross-reactivity with non-gonococcal Neisseria species [54]. Thus, 
particular care should be taken when testing extra-genital samples. 
The report of the high-level CRO-resistant strain F89 [19], harboring a mosaic penA 
XXXIV plus an A501P substitution, subsequently resulted in the development of a modified 
FRET-probe-based RT-PCR with melting curve analysis to detect penA mosaic alleles, as 
well as penA mosaics with A501P or other A501 alterations [55]. Mosaic penA alleles 
including A501P and A501V could be distinguished from penA mosaics with A501 wt and 
A501T, however, the latter two could not be distinguished. When examining 33 NG isolates, 
all four mosaic penA isolates were identified and the A501 variants could be detected (i.e., 
three A501 wt and one A501V). The LOD of the method was comparable with that of the 
original penA mosaic-PCR assay [51]. This RT-PCR was also applied as a first screening tool 
for the detection of mosaic penA in 159 urogenital and extra-genital specimens (of which, 
only two pharyngeal) positive by an in-house PCR. Ten specimens (six rectal and four urine) 
provided positive results, which were subsequently shown to harbor penA A501 wt. However, 
when testing 58 non-gonococcal isolates, 22 provided melting curves in the mosaic501-
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hybPCR with 19 called as mosaic/A501 variants [55]. It would be valuable to further assess 
specificity by testing NG-negative specimens, in order to determine the extent of cross-
reactivity with other bacterial species. Additionally, both the mosaic PCR and the mosaic501-
hybPCR were less sensitive than the in-house duplex assay used to detect NG [55]. 
Furthermore, the sensitivity of the mosaic501-hybPCR to detect the penA mosaic/A501P 
variant could not be estimated, since no such positive clinical samples were available and no 
spiked negative samples were included. Finally, in the developed modified hybridization 
probe format, the probes must remain separate from the reaction mix during PCR 
amplification to avoid inhibition of amplification, which is not effective and/or feasible with 
all RT-PCR systems. 
Two Taqman-based RT-PCR assays to detect mosaic penA alleles and, specifically, the 
mosaic penA allele harbored by the high-level CRO-resistant strain H041 were also developed 
[56]. Both assays had comparable LODs and H041 could be distinguished among 67 NG 
isolates. However, when testing 100 non-gonococcal Neisseria and Moraxella isolates the 
H041-PCR1 showed cross-reaction with N. subflava. Furthermore, using the H041-PCR1 
seven of 50 pharyngeal swabs negative for NG with an in-house PCR were false positive, and 
one of 59 clinical specimens, NG-positive by the same in-house PCR, was also false positive. 
Nevertheless, the H041-PCR2 was negative for all examined non-gonococcal isolates, as well 
as NG-positives (n=39) [56]. These assays share the main limitation of the F89-specific RT-
PCR described above, i.e., no H041-positive samples were available, so further testing of 
spiked NG-negative clinical specimens to estimate sensitivity is recommended. 
 
3.4. Multiple antimicrobials 
Only a few molecular assays predicting resistance to multiple antimicrobials in NG in the 
same test have been reported. 
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The high-throughput Agena Bioscience SNP iPLEX genotyping technology, using mass 
spectrometry, was applied to characterize NG isolates in Australia [57]. The iPLEX-AMR 
method targeted 11 chromosomal AMR determinants, namely 23S rRNA A2059G, 23S rRNA 
C2611T, GyrA S91F, GyrA D95G/A, PBP1 L421P, mtrR adenine-deletion, mtrR thymine-
insertion, MtrR G45D, PBP2 345A insertion, mosaic PBP2, and non-mosaic PBP2 A501T/V. 
This assay was applied together with the previously validated iPLEX-MLST [58] to 
characterize 2452 NG isolates, of which 2218 (90.4%) provided a result in both assays. Some 
samples failed to amplify due to variations in primer-target regions or low template DNA. 
Similar results were obtained when applying both iPLEX assays on additional 1625 NG 
isolates in a further study [59]. Overall, the MassARRAY system showed great potential for 
cost-effective, high-throughput surveillance studies, allowing to genotype up to 384 NG 
isolates per day. However, the applicability for testing clinical specimens is unknown and the 
sequences of the oligonucleotides required for the iPLEX-AMR assay are not available, 
preventing further implementation of the method. 
A multiplex high resolution melting (HRM)-based RT-PCR assay has also been 
developed [60]. This assay included one triplex and three duplex reactions for detection of 
NG (opa, porA) and the 23S rRNA A2059G, 23S rRNA C2611T, GyrA S91F, mosaic penA, 
rpsE Thr24Pro and 16S rRNA C1192T alterations. The assay detected all AMR determinants 
in 39 well-characterized NG isolates, but the overall LOD for proper interpretation of the 
HRM curves was high (i.e., ≥103 to 104 gDNA copies/reaction). Additionally, cross-reactivity 
was observed for several AMR determinants (e.g., 23S rRNA and 16S rRNA) when testing 19 
non-gonococcal Neisseria isolates and eight NG-negative pharyngeal and rectal samples. The 
assay showed 100% sensitivity and 100% specificity for NG identification and in predicting 
phenotypic resistance to CIP, AZM and SPC in a further 193 NG isolates. Sixteen isolates 
with a mosaic penA allele and increased ESC MICs (≥0.064 µg/ml) were also correctly 
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identified. Accordingly, although not feasible for screening of clinical specimens, due to the 
high LODs and cross-reactivity with commensal Neisseria species, this assay can be useful 
for rapid characterization of clinical NG isolates. 
The most comprehensive molecular NG AMR platform designed so far used a multiplex 
bead array suspension assay that included 31 NG-specific chromosomal mutations and 
plasmid genes associated with decreased susceptibility and resistance to PEN, CIP, ESC, 
TET, AZM, and SPC [61]. In six NG control strains a LOD of ∼62 gDNA copies were 
required to detect all AMR determinants. The NG-specific marker porA correctly classified 20 
NG-positive and 50 NG-negative cervicovaginal swabs based on previous in-house RT-PCR 
testing. In 250 NG-positive cervicovaginal swabs, 239 (95.6%) tested positive for porA. The 
detection of AMR determinants varied from 89% to 100%, compared to sequencing. Cross-
reactivity was assessed by testing seven non-gonococcal Neisseria species, 33 other bacterial, 
fungal, and protozoan isolates commonly found in the vaginal environment, and 50 NG-
negative cervicovaginal samples. All samples were negative for porA, but cross-reactivity was 
observed for several AMR determinants, particularly the 16S rRNA determinants. 
Accordingly, the specificity of testing clinical samples, particularly extra-genital specimens, 
can be suboptimal. Furthermore, no positive controls were available for some of the AMR 
determinants, so the sensitivity to detect these could not be determined. The assay requires 
equipment that remains rare in diagnostic laboratories in many settings, but its simplicity, 
relatively low price and flexibility could make it an effective confirmatory test for strain 
typing and predictive assessment of AMR. 
Whole genome sequencing (WGS) allows more comprehensive analysis of both AMR 
prediction and genome-based molecular epidemiology in NG isolates, and costs are falling. 
WGS has been used for full characterization of all known AMR determinants, as well as 
strain typing by phylogenomic analysis and in silico NG multi-antigen sequence typing (NG-
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MAST) and multi-locus sequence typing (MLST) [62-65]. A relatively high reliability of MIC 
prediction for five therapeutic gonorrhea antimicrobials in 681 NG isolates based on a WGS-
based approach has been recently demonstrated [66].  
The first attempt to apply WGS directly on NG-positive clinical specimens has also been 
recently published [67]. Thirteen NG-positive urine samples were sequenced with the Ion 
Torrent technology, obtaining an average depth of coverage based on the FA1090 reference 
genome of 6–130X for the 11 samples. Based on rplF gene and K-mer analysis, the presence 
of commensal bacteria was excluded. AMR determinants associated with resistance to, e.g., 
ESCs, CIP, TET and AZM, were detected. Additionally, new mutations in some AMR 
markers (i.e., gyrA and mtrR) were also identified, although their potential contribution to 
AMR was not confirmed. Finally, all 11 samples could be typed by both NG-MAST and 
MLST. A main limitation was that no paired NG isolates were available, so further studies 
should confirm the accuracy of this method. Nevertheless, this study shows that WGS can be 
successfully applied to obtain extensive typing information directly from clinical specimens, 
suggesting that WGS definitely represents a promising future tool for a more comprehensive 
analysis of both phylogenomics and AMR. 
 
4. Advantages and disadvantages of molecular AMR prediction for N. gonorrhoeae 
Many of the advantages of molecular methods for AMR prediction over culture-based 
methods are those of NAATs in general (Table 2). For example, molecular methods allow to 
dramatically shorten turnaround times from several days to a few hours. Additionally, NAATs 
can be easily automated to increase throughput and decrease hands-on time, which are 
valuable qualities for diagnostic routine settings. From the clinical perspective, molecular 
tests also have higher sensitivity compared with culture, particularly for frequently 
asymptomatic extra-genital infections and can be used to analyze culture negative samples 
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and non-viable previously cultured isolates. Non-invasive self-collected specimen types, such 
as urine and vaginal swabs, can also be used for testing. The improved performance and 
flexibility of sampling for molecular testing could substantially increase sample sizes for NG 
AMR surveillance globally. NAAT-based methods also have the potential to be further 
developed into rapid POC tests in the near future, which would be extremely valuable in 
remote and low technology settings and to guide personalized treatment in all settings. To 
date, no assay that has been developed to predict AMR in NG provides results in <1 hour, a 
definition that is widely applied to POC tests [68]. 
The major disadvantage of molecular prediction of AMR is that an assay will only detect 
known AMR determinants, whilst a culture-based assay will detect the exact level of 
susceptibility or resistance (MICs) that result from any known or new AMR determinants. A 
single molecular assay, with exception of WGS, will not be able to include markers of all 
known AMR determinants and the assay would need to be updated as soon as new AMR 
determinants or sequence variants arise. For these reasons, molecular tests will probably never 
be able to replace culture-based methods completely. Another intrinsic disadvantage of 
molecular AMR assays is that the presence of a molecular AMR determinant may not 
correlate strongly with the MIC of an antimicrobial, because the development of AMR can be 
multifactorial and result from the cumulative effects of several AMR determinants. For 
instance, the detection of a mosaic penA allele in a NG isolate has a relatively high sensitivity 
to predict resistance to ESCs because most ESC-resistant isolates harbor a mosaic penA allele. 
However, the detection of a mosaic penA allele in a NG isolate can also have relatively low 
specificity for the prediction of ESC resistance. Specificity can be relatively low because 
there are many different sequence types of mosaic penA alleles, which result in widely 
different MICs of ESCs, and most mosaic penA alleles do not result in ESC resistance in 
absence of additional ESC AMR determinants (see below). Accordingly, ESC AMR 
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determinants, i.e. mosaic penA alleles, penB, mtrR and Factor X, cumulatively increase the 
MICs of ESCs [2,57,63,69-72]. Notably, a vast majority of mosaic penA-harboring isolates 
reported to be resistant to ESCs belonged to successful strains that spread internationally, 
such as the NG-MAST genogroup 1407 spreading worldwide [2,19-22,73]. Additionally, also 
ESC-resistant strains harboring a non-mosaic penA allele have been described, which encode 
PBP2 with alterations in amino acids A501 and G542/P551 [2,23,24,26].  
Conversely, the association between the main AMR determinants and phenotypic AMR 
appears to be much stronger for some other antimicrobial classes. For instance, the gyrA S91F 
alteration alone has proven to be highly predictive for intermediate susceptibility and 
resistance to CIP. The suitability of this AMR determinant to predict CIP resistance (or 
susceptibility when mutation is lacking) has been shown in several studies performed in many 
different countries worldwide (e.g., Canada [74], Brazil [75], Australia [76], USA [77], and 
Switzerland [78]), and further confirmed by the validation studies of the molecular CIP AMR 
methods mentioned above [44,45,47,60]. Similarly, mutations in at least three 23S rRNA 
alleles have shown to be a good predictor of moderate- to high-level AZM resistance (i.e., 
MIC>2 µg/ml), although low-level resistance may still be observed due to mutations in other 
AMR determinants (e.g., mtrR) [2,35].  
Additional disadvantages common to most molecular AMR prediction methods, 
particularly for pharyngeal specimens, are that: i) sequence variations in primer/probe regions 
may lead to false positive or negative results; ii) several of the developed methods do not 
include an internal control to prevent false-negative results due to low NG DNA loads in the 
samples; and iii) the presence of potentially cross-reacting non-gonococcal Neisseria and 
other bacterial species, which makes the design of NG-specific primers and probes extremely 
complicated, especially for targets sharing a high sequence identity or similarity among 
different Neisseria species (e.g., 23S rRNA). The addition of an internal control to prevent 
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false-negative results due to low NG DNA loads in the samples and thorough validation of all 
molecular assays on extra-genital specimens are essential to increase the validity of existing 
and future assays.  
In general, WGS represents a promising future approach in order to overcome many of 
the challenges with molecular AMR prediction methods.  
 
5. Requirements for using molecular AMR prediction tests to enhance the gonococcal 
AMR surveillance and for guiding personalized treatment of gonorrhea 
The molecular assays developed so far for AMR prediction in NG address a range of AMR 
determinants alone or in combination, might be used on a range of clinical samples and have 
differing performance characteristics. Technical requirements and cost mean that these tests 
are mainly accessible in well-resourced settings. Figure 3 shows that the key requirements of 
a molecular AMR prediction test will differ, depending on their usefulness for different 
applications [68]. Molecular tests will be most readily used for surveillance of NG AMR, 
because archived specimens can be batch-tested retrospectively, and ideal sensitivity and 
specificity are not critical because results will not be used to guide personalized treatment. 
Molecular assays that will be used to guide clinical management need to have high diagnostic 
and AMR predictive accuracy. In a pilot study, the FRET-probe-based RT-PCR for the S91F 
gyrA mutation was used to test NG-positive NAAT specimens to guide treatment for patients 
in California, USA [77]. During the study period, CRO use significantly declined and targeted 
CIP use increased. AMR prediction tests to be used at the POC have the most challenging 
requirements. The assay needs to accurately detect both NG and AMR determinants directly 
in clinical specimens within an hour. At the time of publication of this review, no test fulfils 
these requirements. Even rapid molecular tests for NG detection are not yet fast enough to be 
considered as rapid POC tests. 
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Mathematical modelling studies offer important insights about the potential effects of 
new diagnostic strategies that can help to inform priorities for test development. First, the 
promotion of increased use of screening tests without AMR testing to reduce the prevalence 
of gonorrhea could, paradoxically, increase the spread of resistance to at least some 
antimicrobials such as CIP. Notably, a recently developed mathematical model suggests that 
an increase in the treatment rate of gonorrhea can be the main driver of spread of CIP 
resistance, likely because the increase in empirical treatment imposes selection pressure for 
the emergence of AMR strains [79-81]. Second, POC tests that detect both NG and 
determinants of AMR could control the spread of AMR gonorrhea by allowing personalized 
specific antimicrobial treatment, provided that AMR surveillance continues also with culture-
based phenotypic methods to detect new AMR determinants [81]. These examples highlight 
the importance of modelling studies that can show the trade-offs between strategies to reduce 
gonorrhea prevalence through early diagnosis, treatment and partner notification, and the 
spread of AMR. 
 
6. Expert commentary 
The publications reviewed in this article have refined our understanding of the AMR 
determinants in NG that can be identified easily and accurately and the assays that are most 
likely to be deployed for AMR surveillance, to inform treatment guidelines, and in the future 
to guide personalized treatment and for POC use.   
In countries where levels of CIP resistance remain moderate, i.e. excluding settings in 
Asia with 90-100% resistance, identification of CIP susceptibility would be particularly 
valuable to guide personalized treatment and spare the use of dual antimicrobial therapy 
(CRO plus AZM). The detection of the GyrA S91F alteration has been proven to be highly 
indicative of a CIP-resistant phenotype in several validation and other epidemiological studies 
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[44,45,47,60,74-78]. However, considering the relatively limited number of well-
characterized clinical, and especially extra-genital, samples tested so far, additional testing 
using molecular assays with appropriate controls would be advisable before applying those 
tests on all NG positive NAAT samples. Nevertheless, now is the time to investigate ideal 
implementation (where, when and how) of these assays in the clinical management of 
gonorrhea. Notably, one of these assays has already been introduced in a clinical setting, 
resulting in a significant reduction in CRO use with a concomitant increase in targeted 
therapy [77,82]. 
For the sole detection of AZM resistance determinants in the 23S rRNA gene, only one 
molecular assay has been recently published [50]. Specific mutations in the 23S rRNA, i.e. 
C2611T and A2059G, have been shown to be highly predictive of moderate- (MIC>2 µg/ml) 
and high-level (MIC≥256 µg/ml) resistance to AZM, respectively. However, low-level in 
vitro and clinical resistance to AZM can be due to other AMR mechanisms (e.g., frequently 
mtrR promoter or coding region mutations) [2,8-11,35,36,64]. This method can provide 
clinically relevant data to supplement and enhance culture-based AMR surveillance, and 
enable molecular-based surveillance for AZM resistance. However, since the prevalence of 
the targeted 23S rRNA mutations was very low in the materials tested, further testing of NG 
strains and NG-positive NAAT specimens harboring these mutations to appropriately validate 
the sensitivity of the assay is crucial. For this validation, clinical specimens spiked with 
different concentrations of mutated strains could also be used. Additionally, despite showing 
the potential for good discrimination of commensal bacterial species, some cross-reactivity 
was observed, which resulted in the exclusion of pharyngeal samples for further testing [50]. 
Thus, application of the method on extra-genital, and particularly pharyngeal, specimens 
requires further optimization and validation. 
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The emergence since the 1990s of mosaic penA alleles associated with decreased 
susceptibility and resistance to ESC has led to the development of several assays for the 
detection of different mosaic penA alleles. These methods provide important tools to monitor 
the spread of mosaic penA-harboring isolates, which gives an indication of the ESC 
susceptibility, and have shown promising results also for direct testing of clinical specimens. 
However, many different mosaic penA alleles exist globally and these result in widely 
different MICs of ESCs. Additional AMR determinants, such as non-mosaic penA alleles with 
alterations in PBP2 amino acids A501 and G542/P551, penB, mtrR and Factor X, also further 
increase the ESC MICs [2,23-26,57,63,69-72]. Furthermore, great care should be taken when 
examining extra-genital, especially pharyngeal, specimens, considering the high potential of 
cross-reaction with non-gonococcal Neisseria and even other bacterial species. Finally, 
further assessment of the sensitivity for different sample types is recommended, especially for 
those tests, for which no positive clinical specimen was available.   
Assays targeting AMR determinants for multiple antimicrobial classes might have the 
broadest applicability, but are the most challenging to develop. A rapid HMR curve-based 
assay was developed to screen for the main AMR determinants associated with resistance to 
four different antimicrobial classes, but the limitations encountered during method validation 
prevent application directly on clinical specimens [60]. In contrast, a multiplex bead 
suspension array method appeared to work on clinical specimens [61], but a very limited 
number of samples has been tested so far. Similarly, the only attempt to apply WGS directly 
to urine samples [67] so far requires additional validation on more samples and specimen 
types.  
Overall, several methodologies have been successfully developed in the last few years, 
showing promising results in predicting AMR to different classes of antimicrobials, both in 
isolated NG strains and NG-positive clinical samples. Nevertheless, cross-reactivity with 
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commensal species, particularly but not exclusively Neisseria species, as well as low NG 
DNA loads, especially in extra-genital specimens, still represent major challenges for the 
development of molecular tests sufficiently sensitive and specific for widespread clinical use. 
In this regard, it is also worth noting that several of the published methods do not include 
internal controls to prevent potential false negative samples. Thus, the addition of such 
controls is crucial when applying these methods to clinical, and especially extra-genital, 
specimens. The variability in the correlation between the presence of a particular AMR 
determinant and the expected AMR phenotype is also a main obstacle for several 
antimicrobial classes. For instance, while the GyrA S91F alteration has proven to be a very 
good predictor of phenotypic CIP resistance, ESC resistance is most frequently multifactorial 
at the genetic level and probably also linked to strain-specific genetic backgrounds or other 
still unknown factors. Finally, new AMR determinants or sequence variants will be identified. 
Consequently, some of the molecular AMR methods will require to be updated over time and 
this updating needs to be timely performed. This work needs to be fast-tracked by the 
manufacturer of the assays and regulatory bodies. 
In conclusion, the choice of molecular assay needs to take into careful consideration the 
sample types to which it will be applied, potential limitations intrinsic to NAAT technologies, 
as well as specific to the chosen methodology, and the intended use of the test. 
 
7. Five-year view 
NAATs have become the methods of choice for the detection of NG in many particularly 
well-resourced settings. Their dominance is due to their advantages compared with NG 
culture, including the rapidity and the possibility of automation, dramatically shortening 
turnaround times and hands-on time, while increasing throughput. For these reasons, 
molecular methods for the prediction of AMR in NG will also be increasingly implemented in 
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the near future. Despite their inherent limitations, these molecular tests represent valuable 
tools to improve AMR surveillance by increasing the number of tested samples, and may even 
be soon implemented in diagnostics for personalized treatments.  
Translational research to develop rapid and POC NG tests including AMR prediction, 
ultimately informing tailor-made treatment, will intensify. This research will need to be 
interdisciplinary to integrate highly accurate diagnostic assays with bioengineering solutions 
that allow DNA extraction and performance of the molecular assay including detection. For 
example, microfluidic and nanotechnology approaches are being developed to find low 
technology and even equipment-free assays. These assays will be particularly valuable in 
resource-poor settings where the burdens of AMR and gonorrhea are the highest.  
Preliminary results also suggest that the development of WGS-based methods may in the 
future replace NAAT-based testing for NG AMR prediction, at least in well-resourced 
settings, offering the tempting possibility of a 360° genetic view of strains and samples. In 
fact, WGS displays the major advantage of detecting all known and not-previously discovered 
AMR determinants at the same time, as well as describing the phylogenomics and molecular 
epidemiology. Such methodology will also lead to a deeper understanding of the genetic 
background of the isolates, which in turn may increase our knowledge of potential additional 
factors contributing to increase AMR, virulence and/or fitness in internationally spreading 
clones (e.g., ST1407). 
No methods for molecular prediction of AMR in NG will be able to completely replace 
phenotypic testing, since this would prevent detecting the emergence of new AMR 
determinants and their links to MICs of different antimicrobials, and the accuracy in 
phenotypic AMR prediction based on associated AMR determinants will continue to vary for 
different antimicrobials and NG strains.  
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In conclusion, improved NAAT- and WGS-based methods will continue to supplement 
AMR testing for surveillance purposes, and further translation into POC tests may lead to the 
golden end-goal of personalized treatment, sparing the use of the last available empiric 
treatment options (i.e., ESCs) in order to avert the threat of untreatable gonorrhea. 
 
Key issues 
 The number of genetic assays detecting AMR determinants in NG is increasing, which 
may enhance AMR surveillance and guide treatment guidelines 
 Many genetic assays were relatively successfully applied for both cultured NG isolates 
and direct testing of clinical specimens 
 The accuracy in the AMR phenotype prediction based on the presence of an AMR 
determinant varies dependent on antimicrobials and NG strains 
 The main challenges for the application on extra-genital clinical specimens is cross-
reactivity with other bacterial species and low NG DNA loads 
 More clinical samples and specimen types (especially pharyngeal) should be tested to 
confirm sensitivity and specificity 
 WGS-based approaches will be likely developed in the near future 
 Genetic tests can and should supplement culture-based AMR testing, but will never 
completely replace it 
 Further development of genetic AMR prediction methods into affordable POC tests 
will spare last-line antimicrobials and will be of greatest benefit in resource-poor 
settings 
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Figure legends 
Figure 1. Main antimicrobial targets and mechanisms/determinants conferring resistance to 
ciprofloxacin, azithromycin, extended-spectrum cephalosporins and spectinomycin. Mutations 
or single nucleotide polymorphisms (SNPs): in ponA encoding PBP1 (PBP1 L421P), penA 
encoding PBP2 (PBP2 mosaic, or PBP2 A501 and/or G542/P551 alterations), porB1b 
encoding PorB1b (“penB alteration”; G120±A121 alterations of PorB1b), gyrA encoding 
GyrA (alterations in S91[±D95]), parC encoding ParC (alterations in D86, S87, S88 and/or 
E91), 16S rRNA gene (C1192T mutation), and 23S rRNA gene (C2611T or A2059G 
mutation). OM, outer membrane; PS, periplasmic space; IM, inner membrane  
Figure 2. Membrane organization of the five known drug efflux pumps in N. gonorrhoeae. 
Main drug substrate(s) of NorM is fluoroquinolones; FarAB: fatty acids; MacAB: macrolides; 
MtrF: sulphonamides; and MtrCDE: macrolides, β-lactam antimicrobials (e.g., penicillins and 
cephalosporins) and tetracycline. OM, outer membrane; PS, periplasmic space; IM, inner 
membrane. Modified from Efflux-Mediated Antimicrobial Drug Resistance in Bacteria: 
Mechanisms, Regulation and Clinical Implications, M. Efflux pumps in Neisseria 
gonorrhoeae: contributions to antimicrobial resistance and virulence, 2016, 439-469, Shafer 
WM, Yu EW, Rouquette-Loughlin C, Golparian D, Jerse AE and Unemo Li X-Z, Elkins CA, 
Zgurskaya HI (Eds.) (© Springer International Publishing Switzerland 2016) with permission 
of Springer). 
 
Figure 3. Key features of molecular tests for prediction of antimicrobial resistance (AMR) in 
Neisseria gonorrhoeae, according to intended use. 
Ac
ce
pte
d M
an
us
cri
pt
41 
 
Table 1. Main characteristics of recently published (last five years) molecular methods for prediction of antimicrobial resistance in Neisseria gonorrhoeae. 
Antimicrobial, 
Reference, year  
Methodology Targets Highlights Limitations/notes 
CIP     
Magooa et al., 
2013 [40] 
 
Taqman-based 
RT-PCR 
gyrA wt QRDR   
parC wt QRDR 
(+dcmH for ID) 
Sensitivity (100%) and specificity (97.9%) for NG detection;  
Overall sensitivity and specificity (both 100%) of gyrA for CIP-
susceptibility prediction; 
Overall sensitivity (96.9%) and specificity (100%) for CIP-
resistance prediction. 
 
Overall sensitivity (95.5%)  and specificity (86.1%) of parC for CIP-susceptibility 
prediction; 
Cross-reaction with commensal species for dcmH and parC; 
No extra-genital samples tested. 
Peterson et al., 
2015 [42] 
FRET-probe-
based RT-PCR 
gyrA wt S91 
gyrA wt D95 
parC wt  
(+2 internal CTRs) 
 
Concordance with AMR testing of 100% for gyrA S91 and 
parC D86/ S87/S88, and 99.6% for gyrA D95 in isolates 
(n=252); 
Concordance with AMR testing of 100% for parC in NG-
positive clinical specimens (n=24). 
Undetermined results for both gyrA assays (overall, n=7) for the clinical specimens, 
affecting concordance (83.3%) with AMR testing; 
Potential cross-reaction with commensals (parC, n=2); 
Sample number for paired clinical specimen (n=24). 
Zhao et al., 2012 
[43] 
Taqman-based 
RT-PCR 
GyrA S91F Sensitivity (100%) and specificity (99%) for CIP phenotype 
prediction in isolates and NG-positive clinical specimens 
(n=209) 
 
 
Specimen type of the clinical samples unknown; 
No NG-negative specimens tested; 
No internal CTR. 
Pond et al., 2016 
[44] 
Taqman-based 
RT-PCR 
GyrA S91F 
gyrA wt 
Concordance with AMR testing of 100% in isolates (n=70); 
NG-positive genital (n=174) and extra-genital (n=116) 
specimens tested; 
Sensitivity (95.8%) and specificity (100%) for CIP 
susceptibility prediction in typed NG-positive specimens. 
 
262 of 290 (90%) of clinical specimens could be typed; 
No NG-negative clinical samples tested. 
Buckley et al., 
2016 [45] 
Probe-based 
RT-PCR 
GyrA S91F 
gyrA wt  
“Non-template” bases at the 3’-end of primers to increase 
specificity; 
No cross-reactivity among non-NG isolates (n=55) and NG-
negative clinical specimens (n=171, of which extra-genital 
samples, n=61); 
Concordance with AMR testing of 99% in typed NG-positive 
clinical samples (n=194/210). 
 
195 of 210 (92.9%) of clinical specimens could be typed; 
Number of NG-positive extra-genital specimens (n=21, of which rectal, n=14; 
pharyngeal, n=7). 
Hemarajata et al., 
2016 [49] 
FRET-probe-
based RT-PCR  
GyrA S91F 
gyrA wt  
Further validation of [47];  
Concordance with AMR testing of 100% for isolates (n=100); 
Specificity (100%) for NG-negative specimens (n=116). 
54 of 76 (71%) of clinical specimens could be genotyped; 
No NG-negative pharyngeal samples tested. 
AZM     
Trembizki et al., 
2015 [50] 
FRET-probe-
based RT-PCR 
23S rRNA C2611T 
23S rRNA A2059G 
“Non-template” bases at the 3’-end of primers to reduce cross-
reactivity; 
Correct genotypic characterization of all tested NG isolates 
(n=70); 
Concordance with AMR testing of 97% in paired clinical 
specimens (n=64). 
Cross-reactivity in NG-negative pharyngeal specimens (n=7/21); 
266 of 306 (87%) of clinical specimens could be genotyped; 
No positive clinical specimens for both reactions with paired isolates; 
No internal CTR. 
ESCs     
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Goire et al., 2012 
[52] 
Taqman-based 
RT-PCR
  
Mosaic penA [51] 
penA A501V 
mtrR A-deletion in 
promoter 
High concordance with sequencing results in NG (n=107) and 
non-NG (n=100) isolates for all three assays; 
No false positives in NG-negative clinical specimens (n=192, 
of which, urogenital, n=142; pharyngeal, n=50); 
179 out 179 NG-positive clinical specimens could be typed.  
 
Specimen type of the clinical samples unknown; 
No internal CTR for mosaic penA PCR and penA A501V PCR assays; 
Not all mosaic and non-mosaic penA alleles may be detected with the mosaic penA and 
penA A501 PCR, respectively; 
No paired isolates for the clinical specimens. 
Gose et al., 2013 
[53] 
Taqman-based 
RT-PCR 
Mosaic penA [51] 
Mosaic penA 
XXXIV 
Concordance (100%) with sequencing results for the detection 
of mosaic penA and mosaic penA XXXIV alleles in both 
clinical isolates and positive urine specimens; 
Detection of a novel mosaic penA allele; 
Sensitivity (100%) to detect isolates with alert values of CRO 
MICs (≥0.125 µg/ml). 
 
Only isolates positive by mosaic penA PCR were further tested; 
Urine specimens (n=3) with paired mosaic penA XXXIV isolates, no samples with 
paired non-mosaic penA isolates; 
Limited number of NG-positive and negative specimens and specimen types tested; 
Specificity (57%) to detect alert values of CRO MICs (≥0.125 µg/ml). 
 
Peterson et al., 
2015 [54] 
Probe-based 
RT-PCR 
Mosaic and non-
mosaic penA, porB 
wt, mtrR 
wt/mutation and 
ponA  
(porA for ID) 
 
Agreement with sequencing results of 100% for porA, ponA, 
and penA, 99.6% for mtrR, and 95.2% for porB in clinical 
isolates (n=252); 
Agreement with sequencing results of 100% for porB, 95.8% 
for ponA and mtrR, and 91.7% for penA in paired NG-positive 
clinical samples (n=24). 
Cross-reactivity with non-NG isolates and extra-genital NG-negative clinical samples; 
Limited number of paired NG-positive (n=24, of which extra-genital n=8) and negative 
(n=24) specimens.  
Goire et al., 2013 
[55] 
Modified-
FRET-probe-
based RT-PCR 
Mosaic penA [51]  
Mosaic penA 
A501/A501V/ 
A501T/A501P 
Detection of the mosaic penA XXXIV + A501P allele of strain 
F89;  
Concordance with sequencing results in clinical isolates 
(n=33); 
10 of 159 clinical specimens were correctly identified as penA 
A501. 
 
Mosaic penA A501 and A501 cannot be distinguished; 
19 of 58 non-NG isolates were false positives for penA A501; 
Limited number of pharyngeal specimens tested (n=2); 
No NG-positive specimens for penA A501V/A501T/A501P; 
No internal CTR. 
 
Goire et al., 2012 
[56] 
Taqman-based 
RT-PCR 
H041-like mosaic 
penA allele 
Detection of the mosaic penA allele of strain H041;  
No cross-reactivity in non-NG isolates and NG-negative 
clinical specimens for H041-PCR2. 
 
Cross-reactivity in non-NG isolates and NG-negative clinical specimens for H041-
PCR1; 
No internal CTR; 
No NG-positive specimens; 
Limited number of NG-positive (n=39) specimens tested. 
Multiple classes     
Trembizki et al., 
2012 [57] 
iPLEX-AMR 11 AMR 
chromosomal 
mutations 
Detection of CIP, ESC, AZM, and PEN AMR determinants; 
Applied together with iPLEX-MLST [58] for concomitant 
MLST; 
Large number of screened isolates (n=2452); 
Cost-effective high-throughput screening for surveillance. 
 
No information about iPLEX-AMR method validation and primer sequences; 
Applicability to directly screen clinical specimens unknown; 
2218 of 2452 (90.4%) isolates typed by both iPLEX-AMR and iPLEX-MLST. 
Donà et al., 2016 
[60] 
SybrGreen-
based RT-PCR 
with HRM 
analysis 
7 chromosomal 
AMR mutations 
(+opa and porA for 
ID) 
Detection of CIP, ESC, AZM, and SPC AMR determinants; 
Concordance (100%) with sequencing results for NG isolates 
(n=39); 
Sensitivity (100%) and specificity (100%) for NG identification 
and CIP-, AZM- and SPC-resistance prediction in clinical 
isolates (n=232); 
Sensitivity (100%) to predict CRO resistance. 
 
Overall high LOD for proper interpretation of HRM curves;  
Cross-reactivity with non-NG isolates and NG-negative clinical specimens; 
Limitations do not allow direct screening of clinical specimens; 
Specificity (90%) to predict CRO-resistance; 
Sensitivity (92%) and specificity (94%) to predict CFX-resistance. 
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Balashov et al., 
2013 [61] 
Multiplex bead 
array 
suspension 
assay 
31 AMR genes/ 
mutations 
Comprehensive molecular platform detecting PEN, CIP, ESC, 
TET, AZM, and SPC AMR determinants; 
Sensitivity (95.6%) and specificity (100%) of porA in 
cervicovaginal specimens (n=250); 
Relative simplicity, low price and flexibility. 
No positive CTR for all AMR determinants;  
Limited number of isolates (n=6) used for method validation showing a variable 
detection rate of AMR determinants ranging from 89% to 100%; 
Cross-reactivity, particularly for 16S rRNA reactions; 
No paired NG-positive specimen and other (e.g., extra-genital) sample types tested. 
 
Graham et al., 
2017 [67] 
WGS (Ion 
Torrent) 
Whole genome Detection of ESCs, CIP, TET and AZM AMR determinants in 
NG directly from clinical specimens, including also new 
potential AMR mutations  
 
Only a limited number of urines tested (n=13); 
No paired isolates available to confirm the presence of the detected AMR 
determinants. 
CIP, ciprofloxacin; RT-PCR, real-time polymerase chain reaction; wt, wild type; QRDR, quinolone-resistance determining region; ID, identification; NG, Neisseria gonorrhoeae; CTR, control; AMR, antimicrobial resistance 
(phenotypic); FRET, Fluorescence resonance energy transfer; AZM, azithromycin; ESC, extended-spectrum cephalosporin; CRO, ceftriaxone; HRM, high-resolution melting; LOD, limit of detection; PEN, penicillin; MLST, 
multi-locus sequence typing; SPC, spectinomycin; CFX; cefixime; TET, tetracycline; WGS, whole-genome sequencing.
Table 2. Main advantages and disadvantages of molecular antimicrobial resistance prediction versus phenotypic AMR testing. 
Characteristics 
Molecular AMR prediction Phenotypic AMR testing
Advantages Disadvantages Advantages Disadvantages
Test performance 
Sensitivity higher than culture-based 
methods, especially for extra-genital 
specimens. Can be used on culture-
negative specimens  
Sub-optimal sensitivity and 
specificity for detection of AMR 
determinants in extra-genital 
specimens, owing to cross-reacting 
species  
 
High sensitivity and specificity of  
AMR testing, including for extra-
genital specimens, but limited by the 
lower sensitivity of culture  
Sensitivity of culture lower than 
molecular tests, especially for extra-
genital specimens 
 
Methodology 
Rapid, results available in hours 
 
Detection of potentially emerging 
AMR (first AMR determinants) 
 
Non-invasive specimen types (e.g., 
urine and vaginal samples) 
 
 
AMR resistance can be multi-
factorial, while inclusion of all 
known AMR determinants in one test 
is almost impossible a 
 
Mutations in primer/probe regions 
can lead to false-negatives a 
 
Presence of an AMR determinant 
might not strongly correlate with an 
AMR phenotype 
 
Only known AMR determinants can 
be detected 
 
Exact level of resistance can be 
determined and is clinically relevant, 
i.e., can predict clinical treatment 
failure 
 
Detects AMR in strains with new 
AMR determinants before they have 
been characterized 
 
Requires several days for strain 
isolation and AMR testing 
 
Invasive specimen types, e.g., 
urethral and endocervical 
 
 
Clinical setting 
Short turnaround time, same day if 
necessary 
 
Can be used to increase the number 
of specimens tested 
 
Can be easily automated 
Requires more expensive 
instrumentation, kits and/or more 
advanced technical skills 
Requires minimum material/training High hands-on time and long 
turnaround time limit the number of 
samples processed 
 
Requires viable organisms 
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Does not require viable organisms 
(important in remote settings) 
 
Can be further developed into point-
of-care (POC) tests 
 
 
AMR, antimicrobial resistance 
a Does not apply to whole-genome sequencing technologies 
 
